Celularity Inc. Announces Anticipated Revenues for Second and Third Quarters

Celularity Inc. (NASDAQ: CELU) recently disclosed its expectations for upcoming financial results in a Current Report on Form 8-K filed with the Securities and Exchange Commission. The company, under the leadership of Chief Executive Officer Robert J. Hariri, MD, PhD, foresees revenues from its biomaterial products exceeding $24 million for the six months ending June 30, 2024.

The revenue stream includes earnings from biomaterial product sales and revenues from product licenses, royalties, and other sources, which will reflect as net revenues on Celularity’s income statement. While the financial results for the third quarter and fourth quarter of 2024 aren’t yet finalized, Celularity anticipates over $9 million in net revenue associated with the recently acquired Rebound™ product.

It is important to note that the information provided in the Form 8-K filing remains unaudited and preliminary. As a result, this data doesn’t encompass all the details necessary to comprehensively gauge Celularity’s financial position as of June 30, 2024, September 30, 2024, and December 31, 2024. The company is currently undergoing a review of its consolidated financial statements for the specified periods, and adjustments to the mentioned figures may occur.

The contents of this Form 8-K filing, particularly pertaining to Item 2.02 and Exhibit 99.1 included, are not considered as “filed” for purposes of the Securities Exchange Act of 1934. These details are also not subject to the liabilities of that section. Unless specifically referenced, this information will not be incorporated by default in any filings made under the Securities Act of 1933 or the Exchange Act.

In connection with these disclosures, Celularity has provided additional details in its exhibit within the filing, such as the Letter to Shareholders dated October 22, 2024. The document offers insights into the company’s financial expectations and updates for the mentioned periods.

Investors and stakeholders are encouraged to keep abreast of Celularity’s forthcoming financial announcements as the company progresses with its reviews and finalizes the financial statements.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Celularity’s 8K filing here.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.